AUS
NZ
UK
CA
USA
IND
Highlights:
Oncimmune Holdings PLC has experienced a 7% increase in share price following a successful fundraising initiative and debt restructuring.
The company is set to raise a minimum of £2 million through a share placing, board subscription, and retail stock offer.
In a move to strengthen its balance sheet, Oncimmune has converted half of its €4 million debt to equity, improving its financial position significantly.
Shares in Oncimmune Holdings PLC (LSE:ONC) saw a notable increase of 7% in the first hour of trading, reflecting positive market sentiment towards the company's recent fundraising efforts and debt restructuring initiatives. The autoantibody profiling specialist is poised to raise a minimum of £2 million through a combination of a share placing, a board subscription, and a retail offer of stock.
Simultaneously, the company’s commercial success has enabled it to convert half of its existing €4 million debt into equity. This strategic move has significantly enhanced Oncimmune's balance sheet, allowing for a more manageable debt profile.
Chief Executive Martin Gouldstone expressed gratitude to both investors and the company's debt provider, IPF, for their support in this fundraising endeavor. He stated, “We are grateful to both our investors and debt provider IPF for supporting this fundraising which has enabled a recapitalisation of the business.” The successful completion of this initiative places Oncimmune in a stronger financial position, poised for future growth.
With the improved debt profile and strengthened balance sheet, Oncimmune is positioned to advance the commercialization of its autoantibody profiling platform, which has been gaining significant traction in the market.
As of 8:57 am, Oncimmune shares were trading at 14.9p, reflecting an increase of 1p. The company's proactive measures in securing funding and restructuring debt are seen as pivotal steps towards enhancing its operational capabilities and driving growth in a competitive market.
